COO EPS $1.15 Beats by $0.03, Stock Slides to $54.17 After Revenue Miss

Cooper Companies' earnings put a spotlight on bottom-line resilience versus top-line softness: EPS came in at $1.15 versus the $1.12 consensus, but revenue missed at $1.07B and COO shares opened at $54.17 on Friday, far below their 50-day average of about $72. For market participants, the 0.5% YoY revenue growth and sequential Q4 guidance cut are the central risk factors.

Cooper Companies (NASDAQ: COO) reported its fiscal third quarter 2026 results on Wednesday, September 9, posting earnings per share of $1.15, which beat the Zacks consensus estimate of $1.12 by $0.03. Revenue came in at $1.07 billion, missing analyst expectations of $1.10 billion, while revenue grew just 0.5% on a year-over-year basis. The same quarter in the prior year produced EPS of only $0.49, so the bottom-line improvement was substantial. Management also updated guidance, setting Q4 2026 EPS expectations at $1.050 to $1.090 and full-year 2026 EPS guidance at $4.510 to $4.550.

“

Management also updated guidance, setting Q4 2026 EPS expectations at $1.050 to $1.090 and full-year 2026 EPS guidance at $4.510 to $4.550.

The market reaction was sharply negative. According to The Markets Daily, COO shares traded down $4.21 on Wednesday, closing at $63.48, with volume reaching 8,383,881 shares compared to an average volume of 2,347,124. By Friday, September 11, the stock opened at $54.17, as reported by Ticker Report, placing it near the lower end of its 52-week range and well below both the 50-day simple moving average of about $72 and the 200-day moving average of about $70. The heavy selling suggests investors focused on the revenue miss and soft forward guidance rather than the modest EPS beat.

Financial metrics paint a mixed picture. The company's debt-to-equity ratio stood at 0.23, indicating a conservative balance sheet, while the current ratio of 1.27 and quick ratio of 0.78 reflect adequate near-term liquidity. Return on equity was roughly 10.9% across both reports. However, net margin figures diverged significantly: one source listed 13.46% while the other reported 5.57%, likely reflecting different lookback periods or a data error in syndicated financial summaries. The divergence between EPS growth and revenue growth points to meaningful margin expansion, but the sustainability of that expansion is a key open question.

Institutional activity adds another layer. Mirae Asset Global ETFs Holdings Ltd. raised its stake in Cooper Companies by 48.9% in the first quarter of 2026, bringing its holdings to 22,407 shares valued at $1.89 million. First Trust Advisors LP grew its position by 115.8% in the second quarter, now owning 136,334 shares worth $9.70 million. Cresset Asset Management LLC established a new position worth approximately $291,000, and Cerity Partners LLC increased its holdings. These institutional moves occurred during a period when the stock was already under pressure, which could indicate accumulation at lower valuations or simply broader portfolio adjustments.

Valuation data also show discrepancies between the two reports. One report lists a market capitalization of $10.56 billion and a price-to-earnings ratio of 18.49 at the Friday open price of $54.17. The other lists a market cap of $12.38 billion and a P/E ratio of 53.80 at the Wednesday close of $63.48. The wide range likely reflects different share counts or earnings-per-share calculations. Using the midpoint of the company's full-year 2026 EPS guidance of about $4.53, the Friday open price implies a forward P/E near 12, which would be below typical medical device sector valuations—but only if the guidance proves reliable.